argenx

Transaction highlights

• Kempen crossed one block of 1,050,000 argenx shares for a total of c. USD 130 million, facilitating a smooth transfer of ownership
• Kempen transferred in the recent period over €1.1 billion in argenx shares mainly from early investors to next level institutional investors. This was made possible thanks to our close relationship with argenx, its shareholders and involvement in several ECM transactions (EU IPO 2Q14, US IPO 2Q17, USD 266m 4Q17, USD 301m 3Q18)
• This smoothly executed block trade demonstrates once more Kempen’s added value to European life science companies and its large shareholders whereby limited liquidity requires a specialist approach to accommodate large shareholder movements. At the same time, it also confirms Kempen’s placement power with high quality biotech investors, both in Europe as well as in the US

Company description

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx’s ability to execute on this focus is enabled by its suite of differentiated technologies. The SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows argenx to exploit novel and complex targets, and its three complementary Fc engineering technologies are designed to expand the therapeutic index of its product candidates.